Helicobacter pylori

Overview

Helicobacter pylori is a spiral-shaped, urease-positive bacterium that colonizes the human stomach and is adapted to survive the acidic gastric environment. It is a major cause of chronic gastritis and peptic ulcer disease and is widely recognized as an important risk factor for gastric cancer. Its persistence in the gastric mucosa is supported by virulence mechanisms that promote colonization, inflammation, and tissue injury, making it a clinically significant infectious target in gastroenterology and infectious disease research.

A central biological feature of H. pylori is urease activity, which helps neutralize gastric acid and supports bacterial survival. In addition to direct pathogenic effects, infection can alter gastric mucosal homeostasis and contribute to long-term disease risk. Because eradication can reduce downstream complications, H. pylori remains a major focus of diagnostic innovation, antimicrobial regimen optimization, and studies of host–microbe interactions, including work on gastric cancer prevention and other systemic outcomes.

Focus of Latest Publications

Recent publications on Helicobacter pylori have focused on its pathogenic behavior in host tissues, its role in disease prevention and treatment, and new approaches to local eradication. One study used a three-dimensional bioartificial liver model built with radial-flow bioreactor technology to test whether H. pylori can infect hepatocytes. The bacterium was shown to adhere to hepatocyte surfaces and penetrate intercellular spaces, and infection increased apoptosis about threefold while upregulating TNF-α and activating NF-κB. The same model showed reduced PCNA expression, enhanced Akt activation, and predominantly cytoplasmic β-catenin localization, suggesting that H. pylori may exert direct pathological effects on liver cells.

Several recent studies have examined strategies to control H. pylori infection and its consequences. A polyphenol-rich extract from sea buckthorn leaves was reported to inhibit H. pylori virulence, with activity against multidrug-resistant strains and marked suppression of motility and urease activity. In infected mice, the extract reduced gastric pro-inflammatory cytokines and promoted mucosal protection, while multiomics analysis suggested increased mucosal immunity and enrichment of beneficial gastric microbiota such as Ligilactobacillus and Akkermansia. In another local-therapy approach, polydopamine-functionalized, clarithromycin-loaded nanoparticles were designed for sequential delivery in H. pylori-infected gastric ulcers; these particles showed improved mucus penetration, strong adhesion at the infection site, deep tissue penetration in mice, and nearly complete bacterial reduction with accelerated ulcer healing at a much lower antibiotic dose than conventional systemic therapy.

Additional publications addressed antimicrobial compounds and treatment outcomes. Marine-derived bisabolane-type sesquiterpenes from Aspergillus sp. WHUF04-170 showed moderate in vitro activity against both standard and multidrug-resistant H. pylori strains, and one study compared high-dose dual therapy regimens for first-line eradication. A separate publication summarized evidence that H. pylori treatment reduces gastric cancer risk across all ages. Another study found that H. pylori eradication was associated with a protective effect against osteoporosis progression in females over a 20-year prospective observational cohort, linking eradication therapy to broader systemic outcomes beyond the stomach.

Finally, one publication evaluated TCGA tumor microbiota data and found that detection of H. pylori was less reliable than for some other microbes, highlighting the need for careful validation in host-microbe association studies. Together, these reports emphasize H. pylori as a target in infection biology, gastric disease management, and broader disease-risk research, while also underscoring the importance of improved delivery systems, natural-product-based anti-virulence strategies, and rigorous data interpretation.

Key Publications

• NEWJul A model of Helicobacter infection using an artificial liver constructed by a radial-flow bioreactor. (Human cell, 2026, PMID 42384317): "However, whether Helicobacter pylori (H. pylori) can infect human hepatocytes and how such infection affects hepatocyte structure and function remain unclear."
• Jun Valorization of Sea Buckthorn (Hippophae rhamnocaides L.) Leaves: Polyphenol-Rich Extract Targeting Helicobacter pylori Virulence and Gastric Mucosal Homeostasis. (Journal of agricultural and food chemistry, 2026, PMID 42246387): "This study found that its extract demonstrates a dual mechanism of action, inhibiting bacterial virulence while protecting the gastric mucosa."
• May Systematic evaluation of TCGA tumor microbiota reveals context-dependent reliability. (mSystems, 2026, PMID 42017663): "We found that while the TMPs showed substantial agreement in microbial composition, their accuracy in detecting known oncomicrobes was variable, ranging from excellent for human papillomavirus (HPV) to poor for Helicobacter pylori."
• May Helicobacter pylori treatment reduces gastric cancer risk across all ages. (Drug and therapeutics bulletin, 2026, PMID 42019986): "Preventive Effect of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality: A Korean Population Study."
• Jun Polydopamine-mediated multi-stage delivery for precise local therapy of Helicobacter pylori-infected gastric ulcers. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41921837): "The effective treatment of Helicobacter pylori-infected gastric ulcers requires precise local delivery of antibiotics to the deep-seated pathogens within the inflamed tissue."
• Jun Six previously undescribed bisabolane-type sesquiterpenes from marine derived fungus Aspergillus sp. WHUF04-170 and their antimicrobial activity. (Phytochemistry, 2026, PMID 41651325): "Compounds 9, 10, 15, 16, and 19 exhibited moderate antibacterial activity against both the standard Helicobacter pylori strain G27 and the multidrug-resistant strain HP159..."
• May Comparative Analysis of High-Dose Dual Therapies in First-Line Helicobacter pylori Eradication: An Inverse Probability of Treatment-Weighted Multicenter Study. (The Journal of infectious diseases, 2026, PMID 41617633): "High-dose dual therapy (HDDT) is a promising first-line treatment option for Helicobacter pylori infection."
• May Preventive Effect of Helicobacter pylori Eradication on Osteoporosis in Females: A 20-Year Prospective Observational Cohort Study. (Gut and liver, 2026, PMID 40820207): "This study aimed to ascertain whether HP eradication therapy confers protective effects against osteoporosis progression."